Last Update 06 Dec 25

ZBH: Future Returns Will Depend On Delivering Pipeline And Execution Improvements

Analysts have modestly reduced their average price targets for Zimmer Biomet by high single digits in dollar terms, reflecting tempered expectations for organic growth and near term execution after a mixed Q3, even as they acknowledge ongoing pipeline progress and portfolio diversification.

Analyst Commentary

Street research following the Q3 release reflects a more balanced and nuanced view of Zimmer Biomet, with modestly lower price targets and mixed rating actions signaling both frustration with execution and recognition of underlying strategic progress.

Bullish Takeaways

Bullish analysts emphasize that despite near term volatility, Zimmer Biomet is still delivering mid single digit organic growth, with the FNA acquisition providing an incremental boost to reported revenues and supporting the medium term growth algorithm.
Several positive notes point to ongoing pipeline and portfolio diversification efforts, including encouraging surgeon feedback on newer products such as Oxford Cementless and Osseofit, which are viewed as drivers of procedure share gains and pricing power over time.
Some Buy rated calls argue that recent stock performance already discounts execution missteps and macro headwinds, creating an opportunity if management can stabilize growth trends and demonstrate that commercial and innovation progress translates into more consistent top line delivery.
Even where price targets have been trimmed, bullish analysts generally maintain that valuation remains attractive relative to the broader MedTech group, particularly if Zimmer can re accelerate growth and close the performance gap versus best in class peers.

Bearish Takeaways

Bearish analysts highlight that Q3 results were disappointing relative to expectations, with organic growth missing management's prior targets and international and noncore headwinds raising questions around forecasting discipline and operational visibility.
There is growing concern that 2025 will mark another year of top line deceleration, with JPMorgan and Goldman both flagging a mismatch between management guidance and the underlying demand trajectory, which could continue to pressure valuation multiples.
Relative performance versus leading peers is a recurring theme, as slower knee growth versus top competitors and softness in hips feed the narrative that Zimmer Biomet is at risk of ceding share in key reconstructive categories.
Several cautious outlooks stress that earnings estimates are drifting lower, and that downside to Street expectations for 2026 is possible if the reduced growth outlook persists, limiting near term multiple expansion even if the long term story remains intact.

What's in the News

Received FDA 510(k) clearance for ROSA Knee with OptimiZe, an enhanced robotic-assisted total knee replacement platform that personalizes surgical planning and aims to improve accuracy and reduce user variability, integrated with the Persona Knee System (company announcement).
Granted FDA Breakthrough Device Designation for a first to world iodine treated total hip replacement system, building on recent PMDA approval in Japan and targeting reduced periprosthetic joint infection risk in high risk patients (regulatory update).
Showcased a broad portfolio of robotics and digital solutions at the 2025 AAHKS meeting, including the mBos TKA System, ROSA Knee with OptimiZe, TMINI Miniature Robotic System and the mymobility care management platform, alongside advanced knee and hip implants such as Oxford Cementless and Persona IQ The Smart Knee (conference announcement).
Expanded its trauma offering through the full commercial launch of the Gorilla Pilon Fusion Plating System and Phantom TTC Trauma Nail, targeting complex foot and ankle trauma and pilon fractures with anatomically contoured implants and advanced fixation options (product launch).
Maintained 2025 guidance for reported revenue growth of 6.7% to 7.7%, reaffirming its top line outlook despite mixed execution concerns noted by analysts (guidance update).

Valuation Changes

Fair Value Estimate is unchanged at approximately $102.92 per share, indicating no material shift in intrinsic value assessment.
The Discount Rate has fallen slightly from about 8.75% to 8.70%, reflecting a modestly lower required return in the updated model.
Revenue Growth edged down from roughly 4.78% to 4.73%, implying a slightly more conservative long term top line outlook.
Net Profit Margin increased marginally from about 14.09% to 14.11%, signaling a small improvement in expected profitability.
Future P/E eased slightly from approximately 19.87x to 19.84x, suggesting a marginally lower valuation multiple applied to forward earnings.

Expanding into high-growth segments and leveraging digital health and robotics is boosting recurring revenue, premium product adoption, and margin expansion.
Operational efficiencies, divestitures, and strong US execution are driving improved cash flow and above-market share gains in core orthopedic categories.
Rising pricing pressures, regulatory uncertainties, and execution risks from acquisitions and innovation may hinder Zimmer Biomet's market position, margin stability, and overall growth potential.

Catalysts

About Zimmer Biomet Holdings

Operates as a medical technology company worldwide.What are the underlying business or industry changes driving this perspective?

The growing global elderly population and the rise in chronic lifestyle diseases are expected to accelerate procedure volumes for orthopedic implants and joint replacements, positioning Zimmer Biomet for long-term sustained revenue growth as demand structurally expands.
Strategic acquisitions-such as Monogram Technologies and Paragon 28-are diversifying Zimmer Biomet into higher-growth market segments and introducing innovative, AI-driven robotics, which is projected to enhance future top-line growth and support higher returns on invested capital from 2027 onwards.
The company's focused investment in digital health, robotics, and data-driven surgical solutions (including the ROSA and upcoming Monogram platforms) is increasing adoption of premium offerings, enabling margin expansion due to product mix and driving recurring revenues through connected care ecosystems, supporting higher net margins and earnings predictability.
Operational improvements, supply chain efficiencies, and ongoing portfolio optimization-including divestiture of non-core businesses and disciplined cost management-are resulting in better-than-expected free cash flow generation and improving adjusted net margins even amidst integration expenses from recent M&A.
Zimmer Biomet's strengthened US commercial execution, focus on ambulatory surgery center (ASC) growth, strong pipeline of new product launches, and successful integration of acquired commercial channels are expected to sustain above-market share gains in hips, knees, and extremities, driving organic revenue growth and improved earnings quality over the next several years.

Zimmer Biomet Holdings Earnings and Revenue Growth

Zimmer Biomet Holdings Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Zimmer Biomet Holdings's revenue will grow by 5.5% annually over the next 3 years.
Analysts assume that profit margins will increase from 10.5% today to 14.6% in 3 years time.
Analysts expect earnings to reach $1.3 billion (and earnings per share of $6.55) by about September 2028, up from $823.5 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $1.8 billion in earnings, and the most bearish expecting $924.9 million.
In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 20.4x on those 2028 earnings, down from 25.0x today. This future PE is lower than the current PE for the US Medical Equipment industry at 29.7x.
Analysts expect the number of shares outstanding to decline by 0.49% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 8.22%, as per the Simply Wall St company report.

Zimmer Biomet Holdings Future Earnings Per Share Growth

Risks

What could happen that would invalidate this narrative?

Ongoing industry-wide pricing pressures and potential reimbursement challenges, as evidenced by the company's expectation for selling prices to be roughly flat for the full year, could limit future revenue growth and compress net margins over time.
Increasing competitive intensity, particularly from established players like Stryker (who claim to already possess fully autonomous robotic capabilities), may erode Zimmer Biomet's market share in robotics and core orthopedics, threatening long-term revenue growth and profit sustainability.
Heavy reliance on successful integration and commercialization of recent acquisitions (e.g., Paragon 28 and Monogram Technologies), with admissions that acquisitions have led to a decline in year-over-year operating margins and increased leverage, may introduce risks of execution failures or delayed synergies, negatively impacting both earnings and free cash flow.
Uncertainty around regulatory timelines for disruptive technologies, highlighted by management's cautious language about clinical trials and FDA pathways for fully autonomous robotics, could delay new product launches and slow revenue contributions from these platforms well into the latter half of the decade.
Global tariff exposure and macroeconomic risks, while mitigated for the current year, are described as "fluid" and could worsen unexpectedly in the future (especially with changing global trade dynamics), raising costs and threatening both operating profit and future earnings stability.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $110.917 for Zimmer Biomet Holdings based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $138.0, and the most bearish reporting a price target of just $96.0.
In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $9.2 billion, earnings will come to $1.3 billion, and it would be trading on a PE ratio of 20.4x, assuming you use a discount rate of 8.2%.
Given the current share price of $103.85, the analyst price target of $110.92 is 6.4% higher. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Zimmer Biomet Holdings?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Aging Population And Robotics Will Elevate Orthopedic Care